A5046438294- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Cancer-related Molecular Pathways
- SARS-CoV-2 and COVID-19 Research
- Virus-based gene therapy research
- Respiratory viral infections research
- Metabolism, Diabetes, and Cancer
- Ubiquitin and proteasome pathways
- Inhalation and Respiratory Drug Delivery
Icosagen (Estonia)
2023-2024
University of Tartu
2024
The COVID-19 pandemic represents a global challenge that has impacted and is expected to continue impact the lives health of people across world for foreseeable future. rollout vaccines provided highly anticipated relief, but effective therapeutics are required further reduce risk severity infections. Monoclonal antibodies have been shown be as SARS-CoV-2, new variants concern (VoC) emerge, their utility use waned due limited or no efficacy against these variants. Furthermore, cumbersome...
<h3>Background</h3> ADORA2A, is an adenosine receptor that suppresses immune cell toxicity through sensing extracellular adenosine. ADORA2A belongs to a group of seven-transmembrane proteins called G protein-coupled receptors (GPCRs) which act as detectors various signals from outside the cell. We aim reduce immunosuppressive properties by targeting with monoclonal antibodies (mAbs) enhance potency established immunotherapies. mAbs are attractive modality therapeutically target complex...
Abstract Background: Upregulated glucose metabolism is one of the strategies cancer cells use to fuel their abnormal cell growth and division. Targeting cancer-specific transporter GLUT-1 a promising approach restrict uptake challenge metabolic needs tumor cells. Antibodies, as opposed small molecule inhibitors, are an attractive modality therapeutically target complex muti-pass membrane transporters. Here we report development antibodies that very specifically block function only GLUT-1....
Abstract Background: Alterations in tumor cell metabolism are one of the central processes guiding cancer progression. The increased glucose dependence cells, also known as Warburg effect, opens possibility to therapeutically target glycolytic pathway and challenge metabolic needs cells. We generated 24 monoclonal antibodies targeting main transporter on cells - SLC2A1 (GLUT1). evaluated ability affect fitness alone combination with OXPHOS inhibitors find clinically applicable therapeutics...